公开(公告)号：US20240247230A1

公开(公告)日：2024-07-25

申请号：US18592249

申请日：2024-02-29

Applicant: ALLIFE MEDICINE (BEIJING) LIMITED

Inventor： Yuchun GU ,  Lida WU

IPC: C12N5/079 ,  A61K35/30 ,  A61K38/00 ,  A61P25/28 ,  C07K14/52 ,  C07K14/54 ,  C12N5/00 ,  C12N15/86

CPC classification number: C12N5/0622 ,  A61K35/30 ,  A61P25/28 ,  C07K14/521 ,  C07K14/5403 ,  C07K14/5428 ,  C12N5/0018 ,  C12N15/86 ,  A61K38/00 ,  C12N2500/02 ,  C12N2500/32 ,  C12N2500/38 ,  C12N2500/44 ,  C12N2501/01 ,  C12N2501/12 ,  C12N2501/135 ,  C12N2501/33 ,  C12N2501/999 ,  C12N2506/45 ,  C12N2510/00 ,  C12N2523/00 ,  C12N2740/15043

Abstract: Provided are a genetically modified oligodendrocyte progenitor cell, a preparation method therefor and a use thereof. Also provided is a method capable of simultaneously repairing myelin, promoting myelin production, and reducing inflammatory responses and autoimmune damage; the method comprises a genetically engineered oligodendrocyte progenitor cell achieving direct repair of a myelin sheath by means of transplantation of the genetically modified oligodendrocyte progenitor cell, which can alleviate an inflammatory response of the nerve and improve nerve function. This has very good application prospects in the clinical treatment of multiple sclerosis.

公开(公告)号：US20240043807A1

公开(公告)日：2024-02-08

申请号：US18258781

申请日：2021-12-20

Applicant: iXCells Biotechnologies USA, Inc.

Inventor： Lingyan ZHANG ,  Minqing RONG ,  Nianwei LIN

IPC: C12N5/077

CPC classification number: C12N5/0658 ,  C12N2500/84 ,  C12N2506/45 ,  C12N2501/11 ,  C12N2501/33 ,  C12N2501/727 ,  C12N2501/115 ,  C12N2501/12 ,  C12N2501/105 ,  C12N2501/135

Abstract: Provided herein are methods and compositions for differentiating pluripotent cells, In embodiments, pluripotent cells are differentiated to form myoblast precursor cells, In embodiments, myoblast precursor cells are differentiated to form myoblasts. In embodiments, myoblasts are cultured to form myotubes. Media for culturing cells, cell products, and uses thereof are also described herein.

公开(公告)号：US20230399617A1

公开(公告)日：2023-12-14

申请号：US18250808

申请日：2021-10-27

Applicant: NAGASAKI UNIVERSITY ,  MEGAKARYON CORPORATION

Inventor： Mayumi IWATAKE ,  Yoshinori SUMITA ,  Izumi ASAHINA ,  Makoto SATAKE ,  Yasuko HAZAMA

IPC: C12N5/078

CPC classification number: C12N5/0644 ,  C12N2501/115 ,  C12N2501/105 ,  C12N2501/165 ,  C12N2501/12 ,  C12N2501/155

Abstract: A composition having cell-derived physiological activity is provided. An osteogenic composition includes a treated product obtained by treating megakaryocytes or treating a culture thereof.

公开(公告)号：US20230330183A1

公开(公告)日：2023-10-19

申请号：US18211311

申请日：2023-06-19

Applicant: OCT THERAPIES AND RESEARCH PRIVATE LIMITED

Inventor： Caroline Evette MATHEN

IPC: A61K38/18 ,  C12N5/0775 ,  A61P17/14 ,  A61K38/19 ,  A61K38/17 ,  A61P17/02 ,  A61K47/36 ,  A61K47/02 ,  A61K47/10 ,  A61K38/20 ,  A61K9/00

CPC classification number: A61K38/1825 ,  A61K9/0014 ,  A61K38/1793 ,  A61K38/1833 ,  A61K38/193 ,  A61K38/204 ,  A61K47/02 ,  A61K47/10 ,  A61K47/36 ,  A61P17/02 ,  A61P17/14 ,  C12N5/0668 ,  C12N2501/12 ,  C12N2501/22 ,  C12N2501/2301 ,  C12N2501/2306

Abstract: The present invention relates to a cell-free, stem cell conditioned medium and a process for preparation thereof. Further, the present invention relates to a therapeutic composition comprising the said stem cell conditioned medium for therapeutic and cosmetic purposes. Additionally, the present invention relates to a method for treating dermatological conditions and aiding in hair regeneration by administering the composition of the present invention.

公开(公告)号：US20230287343A1

公开(公告)日：2023-09-14

申请号：US18015489

申请日：2021-07-12

Applicant: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT

Inventor： Asimina GKOUTI

IPC: C12N5/0797 ,  A61P25/14

CPC classification number: C12N5/0623 ,  A61P25/14 ,  C12N2500/99 ,  C12N2501/115 ,  C12N2501/105 ,  C12N2501/12 ,  C12N2501/415

Abstract: A method for generating a three-dimensional neuromuscular organoid in vitro includes providing a first cell culture that includes disease-specific neuromesodermal progenitor cells, 30% to 90% of which co-express BRACHYURY/SOX2 and 10% to 70% of which co-express TBX6. The disease-specific neuromesodermal progenitor cells are cultivated in a first differentiation medium chosen from the group consisting of i) a non-supplemented serum-free cell culture medium and ii) a serum-free cell culture medium supplemented with at least one of a ROCK inhibitor, an activator of a growth factor signaling pathway, and an activator of an insulin signaling pathway. The first differentiation medium is replaced by a second differentiation medium within 1 to 3 days after cultivation start. The second differentiation medium is replaced by a non-supplemented serum-free cell culture medium within another 1 to 3 days. A three-dimensional neuromuscular organoid is obtained from the non-supplemented serum-free cell culture medium.

公开(公告)号：US20230256027A1

公开(公告)日：2023-08-17

申请号：US17766527

申请日：2020-10-08

Applicant: CELLAÏON SA

Inventor： Etienne SOKAL ,  Elisa CORRITORE ,  Sebastien MICHEL ,  Sandrine HORMAN ,  Marine ANGE

IPC: A61K35/407 ,  C12N5/071 ,  A61P7/10 ,  A61P9/00 ,  A61P13/12 ,  A61P11/00 ,  A61P31/00

CPC classification number: A61K35/407 ,  A61P7/10 ,  A61P9/00 ,  A61P11/00 ,  A61P13/12 ,  A61P31/00 ,  C12N5/0672 ,  C12N2500/36 ,  C12N2501/12 ,  C12N2501/15

Abstract: The current invention concerns liver progenitor or stem cells, lysates thereof, and/or conditioned medium obtainable by culturing liver progenitor or stem cells in said medium for use in the treatment of diseases and/or conditions caused by increased vascular permeability or for use in restoring the vascular integrity of cells and tissues in a subject following inflammation and/or infection in said subject. More particularly, the present invention relates to liver progenitor or stem cells or conditioned medium obtainable by culturing liver progenitor or stem cells in said medium for therapeutic use in sepsis and sepsis-induced diseases, such as myocardial edema, acute kidney injury and lung sepsis.

公开(公告)号：US20230235283A1

公开(公告)日：2023-07-27

申请号：US17918971

申请日：2020-04-23

Applicant: PRECEDO PHARMACEUTICALS CO., LTD

Inventor： Qingsong LIU ,  Jie HU ,  Wenchao WANG ,  Cheng CHEN ,  Tao REN ,  Li WANG

IPC: C12N5/071 ,  C12N5/09

CPC classification number: C12N5/0625 ,  C12N5/0693 ,  C12N2501/11 ,  C12N2500/25 ,  C12N2501/727 ,  C12N2501/12 ,  C12N2501/15 ,  C12N2503/02

Abstract: Provided are a primary cell culture medium that contains a combination of an MST1/2 kinase inhibitor and a ROCK kinase inhibitor and is used for culturing primary esophageal squamous cell carcinoma epithelial cells, and a culture method using the primay cell culture medium. In the culture method, the primary cell culture medium is used to culture primay cells on a culture vessel coated with an extracellular matrix glue, so that the primary cells prolilferate rapidly. A cell model obtained by using the primary cell culture medium and the primary cell culture method of the present invention can be used for the efficacy evaluation and screening of drugs.

公开(公告)号：US10072248B2

公开(公告)日：2018-09-11

申请号：US15033405

申请日：2013-11-05

Applicant: BBHC CO., LTD.

Inventor： Sang Yeon Lee ,  Won Ju Jung ,  Ho Bin Kim ,  Min Sun Oh ,  Kye Ho Lee

IPC: C12N5/077 ,  C12N5/071 ,  A61K35/407

CPC classification number: C12N5/067 ,  A61K35/407 ,  C12N5/0665 ,  C12N2500/25 ,  C12N2500/76 ,  C12N2501/10 ,  C12N2501/12 ,  C12N2501/30 ,  C12N2501/33 ,  C12N2501/999 ,  C12N2502/137 ,  C12N2506/13 ,  C12N2506/1369 ,  C12N2506/45

Abstract: The present invention relates to a medium composition containing an Ecklonia cava extract for dedifferentiation an induced pluripotent stem cell. Also, the present invention relates to a method for differentiating an induced pluripotent stem cell produced by using the medium composition into hepatocytes. When using the medium composition according to the present invention, induced pluripotent stem cells using mesenchymal stem cells can be produced efficiently, and the pluripotent stem cells which have been produced can be useful as a cell treatment agent by being capable of being differentiated into hepatocytes.

公开(公告)号：US20180119095A1

公开(公告)日：2018-05-03

申请号：US15539042

申请日：2015-12-25

Applicant: KYOTO UNIVERSITY

Inventor： Kenji OSAFUNE ,  Maki KOTAKA

IPC: C12N5/071 ,  G01N33/50

CPC classification number: C12N5/067 ,  C12N2500/30 ,  C12N2500/62 ,  C12N2501/12 ,  C12N2501/16 ,  C12N2501/237 ,  C12N2501/31 ,  C12N2501/39 ,  C12N2501/727 ,  C12N2501/73 ,  C12N2501/80 ,  C12N2501/999 ,  C12N2506/02 ,  C12N2506/45 ,  G01N33/5067

Abstract: A method for producing hepatocytes from hepatoblasts is provided. The method includes the step of culturing the hepatoblasts in a medium containing a compound selected from the group consisting of pregnenolone and an adrenergic agonist. The hepatoblasts can be obtained by culturing endodermal cells in a medium containing DMSO, and the endodermal cells can be obtained by culturing pluripotent stem cells in a medium containing Activin A and a GSK-3β inhibitor. Accordingly, a method for producing hepatocytes from pluripotent stem cells is also provided by employing the method of the present invention.

公开(公告)号：US20180072995A1

公开(公告)日：2018-03-15

申请号：US15654243

申请日：2017-07-19

Applicant: Koninklijke Nederlandse Akademie van Wetenschappen

Inventor： Toshiro Sato ,  Johannes C. Clevers ,  Meritxell Huch Ortega

IPC: C12N5/071

CPC classification number: C12N5/0671 ,  C12N5/0677 ,  C12N5/0679 ,  C12N5/068 ,  C12N2500/32 ,  C12N2500/38 ,  C12N2501/11 ,  C12N2501/117 ,  C12N2501/119 ,  C12N2501/12 ,  C12N2501/13 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/335 ,  C12N2501/345 ,  C12N2501/415 ,  C12N2501/998 ,  C12N2533/90

Abstract: The invention relates to a method for culturing epithelial stem cells, isolated tissue fragments comprising the epithelial stem cells, or adenoma cells, and culturing the cells or fragments in the presence of a Bone Morphogenetic Protein (BMP) inhibitor, a mitogenic growth factor, and a Wnt agonist when culturing epithelial stem cells and isolated tissue fragments. The invention further relates to a cell culture medium comprising a BMP inhibitor, a mitogenic growth factor, and a Wnt agonist, to the use of the culture medium, and to crypt-villus organoids, gastric organoids, pancreatic organoids, liver organoids, colon organoids, Barrett's Esophagus organoids, adenocarcinoma organoids and colon carcinoma organoids that are formed in the culture medium.